GLP-1 released to the mesenteric lymph duct in mice: Effects of glucose and fat

Regulatory Peptides

Volumn 189, Issue , 2014, Pages 40-45

  Ohlsson, Lena ^a   Kohan, Alison B ^b   Tso, Patrick ^b   Ahrén, Bo ^a  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

DPP 4 inhibition; Fat; GLP 1; Glucose; Incretin secretion; Lymph

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INTRALIPID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENERGY METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; FAT INTAKE; FEMALE; GLUCOSE INTAKE; GLUCOSE METABOLISM; LIPID METABOLISM; LYMPH FLOW; LYMPHOID CELL; MESENTERY LYMPH NODE; MOUSE; NONHUMAN; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN SECRETION; UPREGULATION; ANIMAL; BLOOD; C57BL MOUSE; LYMPH; METABOLISM;

ANIMALS; DIPEPTIDYL PEPTIDASE 4; FEMALE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; LYMPH; MICE; MICE, INBRED C57BL;

EID: 84895731878     PISSN: 01670115     EISSN: 18731686     Source Type: Journal    
DOI: 10.1016/j.regpep.2014.02.001     Document Type: Article

References (32)

1. Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.
2. Ahrén B., Carr R.D., Deacon C.F. Incretin hormone secretion over the day. Vitam Horm 2010, 84:203-220.
3. Vilsboll T., Krarup T., Sonne J., Madsbad S., Volund A., Juul A.G., Holst J.J. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab 2003, 88:2706-2713.
4. Ahrén B. GlP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors. Curr Diabet Rep 2007, 7:340-347.
5. Meier J.J. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 2012, 109:466-474.
6. Ahrén B. Incretin therapy of type 2 diabetes. GLP-1 receptor agonists and DPP-4 inhibitors. J Eur Diabet Nurs 2013, 10:31-36.
7. Gribble F.M. Targeting GLP-1 release as a potential strategy for the therapy of type 2 diabetes. Diabet Med 2008, 25:889-894.
8. Ahrén B. The future of incretin-based therapy. Novel avenues-novel targets. Diabetes Obes Metab 2011, 13(Suppl. 1):158-166.
9. Diakogiannaki E., Gribble F.M., Reimann F. Nutrient detection by incretin hormone secreting cells. Physiol Behav 2012, 6:387-393.
10. Deacon C.F., Nauck M.A., Toft-Nielsen M., Pridal L., Willms B., Holst J.J. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes 1995, 44:1126-1131.
11. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 1999, 85:9-24.
12. Hansen L., Deacon C.F., Ørskov C., Holst J.J. Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 1999, 140:5356-5363.
13. Deacon C.F., Pridal L., Klarskov L., Olesen M., Holst J.J. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol 1996, 271:E458-E464.
14. Ahlkvist L., Vikman J., Pacini G., Ahrén B. Synergism by individual macronutrients explains the marked early GLP-1 and islet hormone responses to mixed meal challenge in mice. Regul Pept 2012, 178:29-35.
15. Yoder S.M., Kindel T.L., Tso P. Using the lymph fistula rat model to study incretin secretion. Vitam Horm 2010, 84:221-249.
16. D'Alessio D., Lu W., Sun W., Zheng S., Yang Q., Seeley R., Woods S.C., Tso P. Fasting and postprandial concentrations of GLP-1 in intestinal lymph and portal plasma: evidence for selective release of GLP-1 in the lymph system. Am J Physiol Regul Integr Comp Physiol 2007, 293:R2163-R2169.
17. Lu W.J., Yang Q., Sun W., Woods S.C., D'Alessio D., Tso P. The regulation of the lymphatic secretion of glucagon-like peptide-1 (GLP-1) by intestinal absorption of fat and carbohydrate. Am J Physiol Gastrointest Liver Physiol 2007, 293:G963-G971.
18. Arnold M., Dai Y., Tso P., Langhans W. Meal-contingent intestinal lymph sampling from awake, unrestrained rats. Am J Physiol Regul Integr Comp Physiol 2012, 302:R1365-R1371.
19. Bollman J.L., Cain J.C., Grindlay J.H. Techniques for the collection of lymph from the liver, small intestine, or thoracic duct of the rat. J Lab Clin Med 1948, 33:1349-1352.
20. Lu W.J., Yang Q., Sun W., Woods S.C., DD́Alessio D., Tso P. Using the lymph fistula rat model to study the potentiation of GIP secretion by the ingestion of fat and glucose. Am J Physiol Gastrointest Liver Physiol 2008, 294:G1130-G1138.
21. Gunnarsson P.T., Winzell M.S., Deacon C.F., Larsen M.O., Jelic K., Carr R.D., Ahrén B. Glucose-induced incretin hormone release and inactivation are differently modulated by oral fat and protein in mice. Endocrinology 2006, 147:3173-3180.
22. Toyozaki M., Osaka M., Kondo Y., Yoshida M. High fat and high cholesterol diet induces DPP-IV activity in intestinal lymph. J Oleo Sci 2013, 62:201-205.
23. Hughes T.E., Mone M.D., Russell M.E., Weldon S.C., Villhauer E.B. NVP-DPP728 (1-[[[2-[5-cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(S)-pyrrolidine), a slow-binding inhibitor of dipeptidyl peptidase IV. Biochemistry 1999, 38:11597-11603.
24. Balkan B., Kwasnik L., Miserendino R., Holst J.J., Li C.U. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia 1999, 42:1324-1331.
25. Reimer M.K., Holst J.J., Ahrén B. Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. Eur J Endocrinol 2002, 146:717-727.
26. Ahrén B., Simonsson E., Larsson H., Landin-Olsson M., Torgeirsson H., Jansson P.A., Sandqvist M., Båvenholm P., Efendic S., Eriksson J.W., Dickinson S., Holmes D. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 2002, 25:869-875.
27. Carr R.D., Larsen M.O., Winzell M.S., Jelic K., Lindgren O., Deacon C.F., Ahrén B. Incretin and islet hormonal responses to fat and protein ingestion in healthy men. Am J Physiol Endocrinol Metab 2008, 295:E779-E784.
28. Carr R.D., Larsen M.O., Jelic K., Lindgren O., Vikman J., Holst J.J., Deacon C.F., Ahrén B. Secretion and dipeptidyl peptidase-4-mediated metabolism of incretin hormones after a mixed meal or glucose ingestion in obese compared to lean, nondiabetic men. J Clin Endocrinol Metab 2010, 95:872-878.
29. Ohlsson L., Alsalim W., Carr R.D., Tura A., Pacini A., Mari A., Ahrén B. Glucose-lowering effect of the DPP-4 inhibitor sitagliptin after glucose and non-glucose macronutrient ingestion in non-diabetic subjects. Diabetes Obes Metab 2013, 15:531-537.
30. Yoder S.M., Yang Q., Kindel T.L., Tso P. Stimulation of incretin secretion by dietary lipid: is it dose dependent?. Am J Physiol Gastrointest Liver Physiol 2009, 297:G299-G305.
31. Parker H.E., Reimann F., Gribble F.M. Molecular mechanisms underlying nutrient-stimulated incretin secretion. Exp Rev Mol Med 2010, 5:12e1.
32. Lindgren O., Carr R.D., Deacon C.F., Holst J.J., Pacini G., Mari A., Ahrén B. Incretin hormone and insulin responses to oral versus intravenous lipid administration in humans. J Clin Endocrinol Metab 2011, 96:2519-2524.